NT-18 PHASE I CLINICAL TRIAL OF ONCOLYTIC VIRUS DELTA-24-RGD (DNX-2401) WITH BIOLOGICAL ENDPOINTS: IMPLICATIONS FOR VIRO-IMMUNOTHERAPY

Delta-24-RGD is a novel replication-competent, tumor-selective, oncolytic adenovirus with enhanced infectivity. Based on promising preclinical studies, we undertook a first-in-human Phase I clinical trial with biological endpoints in order to assess the capacity of Delta-24-RGD to replicate in human...

詳細記述

保存先:
書誌詳細
主要な著者: Lang, Frederick F., Conrad, Charles, Gomez-Manzano, Cande, Tufaro, Frank, Sawaya, Raymond, Weinberg, Jeffrey, Prabhu, Sujit, Fuller, Gregory, Aldape, Kenneth, Fueyo, Juan
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2014
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218426/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou265.17
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料